Ajooni Biotech Limited
NSE: AJOONIMarket Closed • NSE
Day range
52 week range
Ajooni Biotech Limited closed at INR3.02 (-1.31%) on volume 0.59x its 20-day average, trading 45.09% below its 52-week high.
2025-Q1
Q1 FY2025 Financial Results
PAT moved +110.9% QoQ
2024-09-10
AGM Announced
Annual General Meeting
2024-05-07
RIGHTS Announced
Rights 1:1 @ Premium Rs 3/-
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
Low Debt Profile: Debt-to-Equity is comfortable at 0.29x
Attractive Valuation: P/E of 12.1x trades below sector historical averages
Risks
Subject to cyclical raw material and macro industry pressures
Bull case
Market Leadership: Established operational scale in Packaged Foods.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Ownership distribution
Category trends
Hover over a period for exact holdings
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| — | Annual General Meeting | Annual General Meeting | — | 10 Sept 2024 |
| 07 May 2024 | Rights issue | Rights 1:1 @ Premium Rs 3/- | — | 07 May 2024 |
| — | Annual General Meeting | Annual General Meeting | — | 29 Aug 2023 |
| 25 Nov 2022 | Rights issue | Rights 29:30 @ Premium Rs 4/- | — | 25 Nov 2022 |
| 07 Oct 2022 | Dividend | ₹10.00 / share | — | 07 Oct 2022 |
| — | Annual General Meeting | Annual General Meeting | — | 13 Sept 2022 |
| — | Annual General Meeting | Annual General Meeting | — | 17 Sept 2021 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Hindustan Unilever LimitedHINDUNILVR Open analysis | ₹4.45L | 42.46 | 2.32% | ₹17,341.00 | ₹2,680.00 | +10.05% | -3.18% |
 ITC LimitedITC Open analysis | ₹3.30L | 16.64 | 6.06% | ₹19,114.00 | ₹4,509.00 | -11.08% | -15.61% |
 Nestlé India LimitedNESTLEIND Open analysis | ₹2.44L | 59.83 | 0.94% | ₹6,378.00 | ₹959.00 | +25.16% | +48.22% |
 Avenue Supermarts LimitedDMART Open analysis | ₹2.18L | 69.89 | 0.00% | ₹18,795.00 | ₹860.00 | +14.88% | +11.25% |
 Varun Beverages LimitedVBL Open analysis | ₹1.46L | 43.05 | 0.47% | ₹8,451.00 | ₹1,525.00 | +20.44% | +15.09% |
 Britannia Industries LimitedBRITANNIA Open analysis | ₹1.15L | 44.07 | 1.87% | ₹5,000.00 | ₹593.00 | +8.18% | +14.04% |
 Marico LimitedMARICO Open analysis | ₹1.02L | 53.91 | 0.51% | ₹3,957.00 | ₹652.00 | +22.85% | +27.10% |
 UNITED SPIRITS LIMITEDUNITDSPR Open analysis | ₹97,987.65 | 58.11 | 1.23% | ₹3,054.00 | ₹539.00 | +3.67% | +28.03% |
Incorporated in 2010, Ajooni Biotech Ltd is a vegetarian based animal health care solutions company.[1]
IndiaConsumer Defensive
Is Ajooni Biotech Limited Shariah compliant?
Ajooni Biotech Limited is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (3.73%) complies with AAOIFI threshold (≤ 33%).
What is Ajooni Biotech Limited's current valuation relative to peers?
Ajooni Biotech Limited trades at a P/E of 12.1x compared to the sector median of 21.9x, and a Price-to-Book of 0.6x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 0.29x. Interest coverage is 9.7x.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at steady rates while net profit growth averaged consistent levels.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.